Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice by Pao-Pao Yang et al.
RESEARCH Open Access
Effects of dextromethorphan and oxycodone
on treatment of neuropathic pain in mice
Pao-Pao Yang1,2, Geng-Chang Yeh1, Eagle Yi-Kung Huang2, Ping-Yee Law3, Horace H. Loh3 and Pao-Luh Tao2,4*
Abstract
Background: Neuropathic pain is a very troublesome and difficult pain to treat. Although opioids are the best
analgesics for cancer and surgical pain in clinic, only oxycodone among opioids shows better efficacy to alleviate
neuropathic pain. However, many side effects associated with the use of oxycodone render the continued use of
it in neuropathic pain treatment undesirable. Hence, we explored whether dextromethorphan (DM, a known
N-methyl-D-aspartate receptor antagonist with neuroprotective properties) could potentiate the anti-allodynic
effect of oxycodone and underlying mechanisms regarding to glial cells (astrocytes and microglia) activation
and proinflammatory cytokines release in a spinal nerve injury (SNL) mice model.
Results: Oxycodone produced a dose-dependent anti-allodynic effect. Co-administration of DM at a dose of
10 mg/kg (i.p.) (DM10) which had no anti-allodynic effect by itself enhanced the acute oxycodone (1 mg/kg, s.c.)
effect. When the chronic anti-allodynic effects were examined, co-administration of DM10 also significantly enhanced
the oxycodone effect at 3 mg/kg. Furthermore, oxycodone decreased SNL-induced activation of glial cells (astrocytes
and microglia) and plasma levels of proinflammatory cytokines (IL-6, IL-1β and TNF-α). Co-administration of DM10
potentiated these effects of oxycodone.
Conclusion: The combined use of DM with oxycodone may have therapeutic potential for decreasing the effective
dose of oxycodone on the treatment of neuropathic pain. Attenuation of the glial activation and proinflammatory
cytokines in the spinal cord may be important mechanisms for these effects of DM.
Keywords: Oxycodone, Dextromethorphan, Spinal nerve ligation, Neuropathic pain, Allodynia
Background
Neuropathic pain is caused by a primary lesion or dys-
function in the somatosensory system. Symptoms of
neuropathic pain may include hyperalgesia (increased
sensitivity to noxious stimulus) and allodynia (in which
low-threshold stimuli, such as brushing of the skin, can
evoke pain) [1]. Neuropathic pain can be very difficult to
treat with only 40–60 % of people achieving partial relief
[2]. Some animal studies have suggested that activated
microglia in spinal cord may play a vital role in nerve in-
jury induced neuropathic pain [3, 4].
Opioid receptor agonists, such as morphine and oxy-
codone are highly effective strong analgesics for relief of
moderate or severe pain. However, morphine is less ef-
fective in treating neuropathic pain. Chronic morphine
exposure increased glial expression and enhanced proin-
flammatory cytokines in the L5 spinal cord of L5 nerve-
injured rats. This enhanced glial expression followed by
the loss of the analgesic effect of morphine (so called tol-
erance) [5]. Oxycodone is a semisynthetic opioid analgesic
derived from a naturally occurring alkaloid, thebaine. It
has been used in clinic since 1917 and is increasingly used
worldwide to treat acute and chronic pain. Several reports
have shown that oxycodone effectively relieved neuro-
pathic pain in clinic [6, 7]. It is more effective than mor-
phine in the mice models of painful diabetic neuropathy
[7, 8] and sciatic nerve ligation-induced neuropathic pain
[9]. Spinal nerve ligation induced down regulation of
GABAB expression which was prevented by inhibition of
microglia activation in the spinal cord dorsal horn [10].
Recent study by Thibault et al. provided evidence that the
long-term analgesic effect of oxycodone but not morphine
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is due to an up-regulation in GABAB receptor expression
in sensory neurons and subsequently reinforce a presynap-
tic inhibition [11]. Therefore, the first aim of our study was
to investigate whether chronic oxycodone treatment could
suppress the glial activation and proinflammatory cytokines
in a mice model of spinal nerve injury.
Dextromethorphan (DM) has been used in clinics as
an antitussive agent (15–30 mg, 3 to 4 times per day in
adult) for more than 50 years [12]. It can act as low af-
finity non-competitive N-methyl-D-aspartate (NMDA)
receptor antagonist [13], α3β4-nicotinic receptor antagonist
[14], and sigma-1 receptor agonist [15]. Our previous stud-
ies showed that DM could effectively reduce the rewarding
effects (i.e., addiction potential) and drug-seeking effects of
morphine [16, 17] or methamphetamine [18, 19] in rats.
DM also has important neuroprotective properties in vari-
ous CNS injury models, including ischemia, seizure, and
traumatic brain injury paradigms [20]. Co-administration of
L-NAME (nitric oxide synthase inhibitor) and DM pre-
vented pathological pain in sciatic nerve ligation induced
neuropathy in the chronic constriction injury (CCI) model
[21]. DM blocks LPS-induced microglial activation in a
concentration-dependent manner in vitro [22, 23] and also
inhibits methamphetamine-induced microglial activation
in vivo [22]. Many of these effects of DM seem functionally
related to its inhibitory effects on glutamate-induced neuro-
toxicity via NMDA receptors or voltage-gated calcium
channel activities [24]. Since oxycodone still has high
abused and addictive potential and all the side effects of
opiates at the therapeutic doses, the second aim of our
study was to investigate whether DM at a dose that did not
have anti-allodynic effect by itself could potentiate the effect
of oxycodone on treatment of neuropathic pain and there-
fore decrease the effective dose of oxycodone in a mice
model. The underlying mechanisms regarding to suppres-
sion of glia activation and proinflammatory cytokines were
also investigated in the present study.
Methods
Animals
One hundred and twenty three adult male C57BL/6 J mice
(25–30 g; from mating of the parental C57BL/6 J strain)
were used in this study. The animals were kept in an
animal room with a 12-h light/dark cycle, at a temperature
of 25 ± 2 °C and humidity of 55 % at the Animal Center of
Taiwan’s National Defense Medical Center, which is accre-
dited by AAALAC International. Standard diet and water
were provided ad libitum during the experiment. The care
of animals was carried out in accordance with institutional
and international standards (Principles of Laboratory
Animal Care, NIH), and the protocol was approved by the
Institutional Animal Care and Use Committee (IACUC) of
National Defense Medical Center, Taiwan, ROC. All studies
involving animals are reported in accordance with the AR-
RIVE guidelines [25].
Spinal nerve ligation (SNL) surgery
L5 SNL was carried out according to a previously de-
scribed method for rats [26] and modified for mice in our
laboratory [27]. The mice were deeply anesthetized with
sodium pentobarbital (80 mg/kg, i.p.), and the hairs on
their back were clipped. A midline incision above the lum-
bar spine exposed the left sixth lumbar transverse process.
The transverse process was removed carefully with a small
scraper. The underlying fifth lumbar nerve root was iso-
lated and then tightly ligated with 8–0 nylon thread. Next,
the wound was closed with 2–3 muscle sutures (3–0 ab-
sorbable nylon suture) and 4–5 skin sutures (3–0 non-
absorbable nylon suture). The surgical procedure for the
sham group was identical, except that the fifth lumbar
spinal nerve was not ligated and transected.
Experimental schedule and groups
As shown in Fig. 1, a 14-day schedule was used in this
study. Drug(s) was/were administered from 2 h after spinal
nerve ligation surgery in mice (once on day 0 and day 14,
twice a day from day 1 to day 13). Von Frey tests were used
for measuring mechanical allodynia every other day. Two
tests were carried out in mice on each test day. The first
one was tested 1 h before drug(s) administration, in order
to see the development of allodynia under chronic drug(s)
treatment. The second test was tested 30 min after drug(s)
administration in order to see the acute anti-allodynic ef-
fect of drug(s). There were more than 10 groups based on
different drug(s) treatment, such as sham operation with
saline treatment (sham + saline), SNL surgery with saline
Fig. 1 The schedule of the experiments
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treatment (SNL + saline), SNL surgery with DM treatment
(10 mg/kg, i.p. or 20 mg/kg, i.p.) (SNL +DM10, SNL +
DM20), SNL surgery with oxycodone treatment (1, 3, or
5 mg/kg, s.c.) (SNL +O1, SNL +O3 or SNL +O5), and
SNL surgery with co-treatment with oxycodone (1 or
3 mg/kg, s.c.) and DM (10 mg/kg, i.p.) (SNL +O1 +DM or
SNL +O3 +DM). The animals were given the last drug ad-
ministration 30 min before sacrificed on day 14 for im-
munohistochemistry study. The number of animals in
each group was at least 8 at the beginning of the ex-
periment; and at least 5 mice in each group survived to
complete this study.
Von Frey test for determination of mechanical allodynia
The mice were individually placed in a transparent acrylic
box (9 × 9 × 15 cm) with a wire-mesh bottom and allowed
to acclimate to their environment for at least 30 min. The
mechanical stimulus was applied from underneath to the
plantar aspect of the hind limb, with a gradual increase in
pressure by means of an Electronic von Frey apparatus
(IITC Inc., CA, USA). The end point was characterized by
the removal of the paw followed by clear flinching move-
ments. After the paw withdrawal, the intensity of the pres-
sure was automatically recorded. The test was carried out
1 h before (pretest) and 30 min after saline or drug(s) in-
jection. Each test was repeated 3 times with intervals of
5 min, and the average value was used. The area under the
time-effect curve (AUC) was calculated for each animal
according to the following formula: |(paw withdrawal
pressure of each time point) – (paw withdrawal pressure
of pre-operative baseline value)| × time (days).
Immunohistofluoresensce for activated spinal astrocytes
or microglia
Mice were anesthetized with pentobarbital (80 mg/kg i.p.)
30 min after saline or drug administration on day 14 and
perfused with Tyrode’s calcium-free buffer (116 mM
NaCl/5.36 mM KCl/1.57 mM MgCl2.6H2O/0.405 mM
MgSO4/1.23 mM NaH2PO4/5.55 mMglucose/26.2 mM
NaHCO3, pH 7.4), followed by 4 % paraformaldehyde in
0.1 M phosphate buffer (pH 7.4). The L4-L6 spinal
segments were carefully removed, post-fixed in the same
fixative for 2 h at 4 °C, and then placed in 30 % sucrose
solution for 48–72 h at 4 °C. The samples were then
embedded in OCT compound and frozen immediately
at −80 °C. Serial transverse spinal cord slices (10 μm)
were sectioned with a cryostat. The slices were mounted
on SuperFrost Plus slides (Menzel-Glaser) and were air-
dried for 30 min at room temperature, and washed three
times in ice-cold phosphate-buffered saline Tween-20
(PBST). The slices were then fixed by immersing the slides
in acetone/methanol (1:1, pre-cooled to −20 °C) for 3 min
and washing them again three times in ice-cold PBST.
The sections were then pre-incubated with blocking buffer
(3 % normal goat serum diluted in PBST) for 1 h at room
temperature. After washing in ice-cold PBST, the sections
were incubated overnight at 4 °C with mouse monoclonal
anti-GFAP antibody (1:400; Millipore, Cat #MAB360) or
incubated over 2 nights with rabbit anti-iba1 antibody
(1:300; Wako), which was diluted in PBS. Following pri-
mary antibody incubation, the sections were washed three
times with PBST and incubated with the secondary anti-
body [goat anti-mouse FITC conjugated (1:100, Millipore,
Cat #AP124F), or Alexa Fluro 488 goat anti-rabbit IgG
(1:200), which were diluted with blocking buffer] for 1 h
at room temperature. Sections were then washed with
PBST, cleared, and cover-slipped by using mounting
medium (Serotec, HIS002B). The processed sections were
captured using a Leica (DMI 6000B) inverted microscope
and a Leica (DFC 420) camera by MetaMorph software
(Major Instruments Co., Ltd). Five spinal cord sections
from the L5 segments were randomly selected from each
mice. So in each group, there were 30 sections obtained
for histology quantifications. Images were evaluated by a
computer-assisted image analysis program (MetaMorph
6.1). Our image data were collected using the same region
and the same size of field within same lamina to avoid any
variance and difference in staining between lamina. The
immunoreactivities for GFAP and iba1 immunopositive
cells within the superficial dorsal horn were averaged the
spinal sections for each experimental group.
Quantification of cytokine levels using xMAP technology
Blood samples were collected on day 2 and day 6 after
spinal nerve ligation surgery in mice. Blood was mixed
with 1.8 mg/ml EDTA and put on ice for less than 10 min.
Plasma was then collected by centrifugation at 1000 g for
10 min at 4 °C and stored at −80 °C until analysis. Cyto-
kine levels were determined using the Milliplex MAP
mouse cytokine/chemokine kit (Millipore, Billerica, MA,
USA; MCYTOMAG-70 K), with specific bead sets – pro-
inflammatory cytokines (IL-6, IL-1β, and TNF-α). The
data acquisition and analysis were performed using Milli-
plex Analyst 5.1.
Statistical analysis
The data were expressed as means ± S.E.M. Student’s t
test, two-way or one-way ANOVA, Bonferroni post hoc
test, or Newman-Keuls test were used to analyze the data.
A difference was considered to be significant at p < 0.05.
Results
Effects of oxycodone on SNL-induced allodynia
We first explored the effects of oxycodone on the mech-
anical allodynia induced by SNL. The withdrawal pressure
for ipsilateral hind paw was significantly decreased from
7–9 g to around 2 g on day 3 after SNL surgery (SNL + sa-
line group in Fig. 2a). On the other hand, the sham
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operation did not alter the ipsilateral hind paw withdrawal
pressure at all (sham + saline group in Fig. 2a). These re-
sults indicate that the allodynia of the ipsilateral hind paw
was induced by the ligation of the L5 spinal nerve. The
withdrawal pressure of the contralateral side of the nerve-
ligated group did not change significantly through the
time course (data not shown).
Furthermore, the withdrawal pressure of the ipsilateral
hind paw was determined 1 h before and also 30 min after
saline or oxycodone treatment (1, 3, or 5 mg/kg, s.c.) every
other day. There was a dose-dependent acute anti-allodynic
effect of oxycodone when tested 30 min after drug adminis-
tration, as shown in Fig. 2a. Oxycodone at a dose of 5 mg/
kg (s.c.) completely blocked the allodynia of the ipsilateral
hind paw in all test days. The corresponding area under
curve (AUC) of the time-effect curves also showed that
the oxycodone had a dose-dependent anti-allodynia effect
(Fig. 2b). However, this acute effect of oxycodone did not
persist. When we measured the withdrawal pressure of the
ipsilateral hind paw 1 h before drug treatment on test days,
though there was significant attenuation of the allodynia,
the chronic effects of oxycodone were much less than the
acute effects of oxycodone [Fig. 2c, d vs. Fig. 2a, b]. These
data indicate that oxycodone (1, 3, or 5 mg/kg, s.c.) not
only had an acute anti-allodynic effect but also could
improve the chronic course of the SNL-induced allodynia.
Effects of DM on SNL-induced mechanical allodynia
We next investigated the effects of DM by itself on the
mechanical allodynia induced by SNL. As shown in Fig. 3a,
20 mg/kg of DM (i.p.) produced a minimal but significant
anti-allodynia effect in SNL mice (Fig. 3a, SNL +DM20 vs.
SNL + saline group; p < 0.001). On the other hand, 10 mg/
kg of DM did not produce any acute anti-allodynia effect
after daily drug treatment in SNL mice (SNL +DM10 vs.
SNL + saline group). Neither 10 mg/kg nor 20 mg/kg of
DM by itself showed significant chronic effects when tests
were done 1 h before drug treatment, as shown in Fig. 4a.
Hence, in the following studies, we chose a dose of DM
that by itself had no acute anti-allodynic effect, i.e.,
10 mg/kg (i.p.), to co-administer with different submaxi-
mal doses of oxycodone (i.e., 1 or 3 mg/kg, s.c.) so as to
investigate whether DM could enhance the anti-allodynic
effect of oxycodone.
Co-administration of DM with oxycodone on SNL-induced
allodynia
The acute anti-allodynic effect of oxycodone was dose-
dependent, as previously shown in Fig. 2b. When mice
were treated with drug(s) after SNL (twice a day from day
1 to day 13) and the Von Frey tests were done every other
day, we found that oxycodone by itself at a lower dose, i.e.,
1 mg/kg, improved the allodynia partially, as shown in the
Fig. 2 Oxycodone produced a significant and dose-dependent acute effect on SNL-induced allodynia. The ipsilateral paw withdrawal pressure
was determined every other day after SNL by von Frey test. (a) acute effect determined 30 min after daily saline or oxycodone administration, or
(c) chronic effect determined 1 h before saline or oxycodone administration. The area under curve (AUC) values of corresponding curves of the
von Frey tests are shown in (b) and (d). Data are presented as means ± S.E.M. (n = 5–9). One-way ANOVA and Newman-Keuls test were used to
analyze the data. *P < 0.05, ***p < 0.001 vs. Sham + saline group; #p < 0.05, ###p < 0.001 vs. SNL + saline group
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Fig. 3b. Co-administration of DM (10 mg/kg, i.p.) en-
hanced the acute effect of oxycodone (1 mg/kg, s.c.) min-
imally but significantly (Fig. 3b, p < 0.05). However, this
combined treatment did not improve the chronic effect of
oxycodone (1 mg/kg, s.c.) if tested 1 h before oxycodone
administration every other day, as shown in Fig. 4b.
The acute anti-allodynic effects of oxycodone at a higher
dose of 3 mg/kg were shown in Fig. 3c. It could be seen
that the AUC value of oxycodone (3 mg/kg) was much less
than that in the SNL + saline group (p < 0.001) but still lar-
ger than that in the sham+ saline group (Fig. 3c, p < 0.05).
There is an apparent enhancement of anti-allodynic effects
of 3 mg/kg oxycodone with the co-administration of DM
(10 mg/kg) as demonstrated by no significant difference in
the AUC value between this group and that of the sham +
saline group (Fig. 3c). More importantly, when the Von
Frey tests were done 1 h before drug treatment every
other day, co-administration of DM (10 mg/kg) with
3 mg/kg of oxycodone significantly enhanced the chronic
anti-allodynic effects of oxycodone, as shown in Fig. 4c,
suggesting that this combined use of DM (10 mg/kg) with
oxycodone (3 mg/kg, s.c.) could further alleviate the devel-
opment of chronic allodynia.
Oxycodone suppressed the SNL-induced activation of
astrocytes and microglia
Morphological changes of astrocytes and microglia during
allodynia under SNL-induced neuropathic pain were
examined by carrying out immunohistofluoresence stud-
ies. In the sham-operated group (sham + saline), GFAP-
immunopositive astrocytes had a less ramified morph-
ology. In contrast, SNL induced significant activation of
astrocytes manifested by a strong GFAP immunoreactivity
and hypertrophic morphology in the dorsal spinal cord
(L5) of ipsilateral side, which could be seen on day 14 after
SNL surgery (Fig. 5a). Quantification of immunoreactivity
Fig. 3 DM (10 mg/kg, i.p.) enhanced the acute effect of oxycodone (1 mg/kg, s.c.) on SNL-induced allodynia. The ipsilateral paw withdrawal pressure
was determined 30 min after saline or drug administration every other day after SNL. (a) effects of DM10 (DM, 10 mg/kg, i.p.) or DM20 (DM, 20 mg/kg,
i.p.); (b) effects of O1 (oxycodone, 1 mg/kg, s.c.) or O1 + DM10; (c) effects of O3 (oxycodone, 3 mg/kg, s.c.) or O3 + DM10. Data are presented as means
± S.E.M. (n = 5–9). One-way ANOVA and Newman-Keuls test were used to analyze the data. *P < 0.05, ***p < 0.001 vs. Sham+ saline group; ###p < 0.001
vs. SNL + saline group; &p < 0.05 vs. SNL + O1 group
Fig. 4 DM (10 mg/kg, i.p.) enhanced the chronic effects of oxycodone (3 mg/kg, s.c.) on SNL-induced allodynia. The ipsilateral paw withdrawal
pressure was determined every other day after SNL at about 1 h before daily saline or drug administration. (a) effects of DM10 (DM, 10 mg/kg, i.p.) or
DM20 (DM, 20 mg/kg, i.p.); (b) effects of O1 (oxycodone, 1 mg/kg, s.c.) or O1 + DM10; (c) effects of O3 (oxycodone, 3 mg/kg, s.c.) or O3 + DM10. Data
are presented as means ± S.E.M. (n = 5–9). One-way ANOVA and Newman-Keuls test were used to analyze the data. ***P < 0.001 vs. Sham + saline
group; #p < 0.05, ###p < 0.001 vs. SNL + saline group; &p < 0.05 vs. SNL + O3 group
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Fig. 5 (See legend on next page.)
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by measuring the intensity of the staining indicated signifi-
cant increase of GFAP immunoreactivity by SNL (4.1-fold
on day 14), as compared with the sham control group
(sham + saline) (Fig. 5b). Daily treatment with oxycodone
(1 mg/kg) significantly suppressed SNL-induced activation
of astrocytes (Fig. 5a, b).
The microglia with a resting ramified morphology by
staining with a marker (iba1) were observed at the ipsi-
lateral side of the dorsal spinal cord of sham-operated
mice on day 14 (Fig. 6a). On the other hand, hyper-
trophic and amoeboid morphology of microglia in SNL
mice were seen on day 14, indicating that microglia were
more activated in SNL mice than those in sham-operated
mice (Fig. 6a). The immunoreactivity of iba1 was also
markedly increased in the ipsilateral L5 spinal cord dorsal
horn (4.6-fold increase) after spinal nerve ligation for
14 days (SNL + saline group), as compared with the sham
control group (sham + saline) (Fig. 6b). Oxycodone (1 mg/
kg) significantly suppressed SNL-induced microglia activa-
tion, as shown in Fig. 6b.
DM potentiated the effect of oxycodone in suppressing
the SNL-induced activation of astrocytes and microglia
Daily treatment with DM (10 mg/kg) by itself slightly
but significantly suppressed SNL-induced activation of
astrocytes (Fig. 5a). After daily co-administration of oxy-
codone (1 mg/kg) with DM (10 mg/kg), some activated
astrocytes were reversed to the resting state, as indicated
by a further decrease in GFAP-positive cells (Fig. 5a, b).
DM (10 mg/kg) alone did not suppress the SNL-induced
microglia activation, as shown in Fig. 6b. However, co-
administration of DM with oxycodone potentiated the ef-
fect of oxycodone and further inhibited the SNL-induced
microglia activation to the control (sham+ saline) level
(Fig. 6b). These results suggest that DM can enhance the ef-
fects of oxycodone (1 mg/kg) in suppressing the SNL-
induced activation of both microglia and astrocytes. Since
this effect of DM+O1 has reached the maximal effect, we
did not further do the immunostaining for DM+O3 group.
The plasma level of SNL-induced pro-inflammatory
cytokines was reduced by oxycodone or co-administration
of DM with oxycodone
Spinal-nerve injury induces rapid production and re-
lease of proinflammatory mediators [28, 29]. Therefore,
whether co-administration of DM with oxycodone would
enhance the effect of oxycodone on pro-inflammatory cy-
tokines in plasma for each group on day 2 and day 6 after
SNL surgery were determined. As shown in Fig. 7, SNL in-
duced a significantly higher plasma level in all three pro-
inflammatory cytokines we measured — i.e., interleukin-6
(IL-6, Fig. 7a), interleukin-1β (IL-1β, Fig. 7b), and tumor
necrosis factor alpha (TNF-α, Fig. 7c) — on day 2 and day
6 after spinal nerve ligation. These increases were sup-
pressed by either the treatment of oxycodone alone
(1 mg/kg) or co-administration of DM (10 mg/kg) with
oxycodone (1 mg/kg) (Fig. 7a, b, c). DM (10 mg/kg) by
itself reduced the plasma concentration of IL-1β
(Fig. 7b) and TNF-α (Fig. 7c) on day 2 and/or day 6
after surgery, but did not affect the plasma level of IL-6.
When DM (10 mg/kg) was co-administered with oxy-
codone, it seemed to further decrease the plasma levels of
IL-1β and TNF-α, which were already suppressed by oxy-
codone (1 mg/mg), although this did not achieve statistical
significance.
Discussion
The present study demonstrates that acute administration
of oxycodone (1–5 mg/kg, s.c.) suppressed SNL-induced
mechanical allodynia in a dose-dependent manner. DM at
a low dose (10 mg/kg, i.p.) potentiated this acute effect of
oxycodone. More importantly, it also alleviated the devel-
opment of chronic allodynia better than use of oxycodone
(medium dose, 3 mg/kg, s.c.) alone. We found that chronic
oxycodone significantly suppressed the activation of astro-
cytes and microglia in the spinal cord and also the plasma
level of proinflammatory cytokines (IL-6, IL-1β and TNF-
α). Furthermore, co-administration of DM with oxy-
codone showed better effects than oxycodone alone in
suppressing the SNL-induced activation of astrocytes and
microglia in the dorsal horn of spinal cord and also
showed a trend to enhance the effect of oxycodone on de-
creasing the plasma level of proinflammatory cytokines.
Oxycodone is an agonist acting on opioid receptors
which are all coupled to the G proteins and distributed
in the central and peripheral nervous system [30]. Oxy-
codone has been used in clinic for the treatment of can-
cer and neuropathic pain for many years [6]. Similar to
other opiate drugs, oxycodone at high doses may have
many side effects, including sedation, dizziness, nausea,
(See figure on previous page.)
Fig. 5 Co-administration of DM (10 mg/kg, i.p.) and oxycodone (1 mg/kg, s.c.) enhanced the effect of oxycodone to suppress SNL-induced activation of
astrocytes in the L5 spinal cord dorsal horn. (a) Representative immunofluorescent images of astrocytes stained with GFAP (green; marker for activated
astrocyte) on day 14 is shown for the following groups: Sham (ipsilateral), SNL (contralateral), SNL (ipsilateral), SNL-DM10 (DM 10 mg/kg, i.p.; ipsilateral),
SNL-O1 (oxycodone 1 mg/kg, s.c.; ipsilateral), and SNL-O1 + DM10 (co-administration of oxycodone and DM; ipsilateral) (magnification: 20X). Scale bar,
50 μm. (b) Quantification of GFAP-immunoreactivity after normalization for each group compared with control group (Sham+ saline) on day 14. Data are
presented as means ± S.E.M. (n≥ 5). One-way ANOVA and Newman-Keuls test were used to analyze the data. *P< 0.05, **p < 0.01, ***p< 0.001 vs. Sham+
saline group; #p < 0.05, ###p< 0.001 vs. SNL + saline group; &p < 0.05 vs. SNL +O1 group
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vomiting, constipation, respiratory depression, depend-
ence, and tolerance.
After peripheral nerve injury, spinal sensory neurons
(DRG neurons) increased sodium-channel expression on
sensitized primary afferents leads to increase of glutamate
release from the nerve endings. Glutamate, released from
pre-synaptic terminal, binds post-synaptic ionotropic and
metabotropic receptors, leading to calcium influx through
NMDA and AMPA receptors and activate protein kinase
which may contribute to increase gain in the pain trans-
mission system [31]. DM is a commonly used antitussive
drug. It acts as a low-affinity non-competitive NMDA re-
ceptor antagonist and a high affinity sigma-1 receptor
agonist, and it suppresses glutamate-induced excitotoxi-
city in the CNS and spinal regions [13]. Structurally, it is
closely related to levorphanol, codeine, and morphine, but
is dextrorotary in form. Therefore, it has low affinity for
opioid receptors and is not considered to be addictive.
NMDA receptor antagonists (such as MK-801 and keta-
mine) and sigma receptor agonists have been reported to
have anti-inflammatory effects [32, 33]. In our results,
acute administration of DM alone at a dose of 10 mg/kg
(i.p.) did not show a significant anti-allodynic effect in
SNL mice, whereas acute administration of DM at a dose
of 20 mg/kg (i.p.) elicited a slight but significant anti-
allodynic effect in this model (Fig. 3a). Recently, several
clinical studies have shown that high doses of DM (270–
400 mg/day) have analgesic effects to neuropathic pain
with traumatic origin or diabetic neuropathy, but not with
post-herpetic neuralgia [34, 35]. Additionally, low doses of
DM (90 mg/day or less) did not relieve chronic neuro-
pathic pain [36] or neuropathic pain resulting from cancer
[37]. In rat studies, DM (40 mg/kg, i.p.) and its metabolite
dextrophan (20–40 mg/kg, i.p.) induced PCP-like side ef-
fects (memory and psychotomimetic disturbances); but
10–30 mg/kg (i.p.) of DM did not impair reference
Fig. 7 Effects of DM (10 mg/kg, i.p.) and oxycodone (1 mg/kg, s.c.) on SNL-induced plasma level of pro-inflammatory cytokines: (a) IL-6, (b) IL-1β, and
(c) TNF-α on day 2 (D2) and day 6 (D6) after SNL surgery. Data are presented as means ± S.E.M. (n = 7–12). One-way ANOVA and Newman-Keuls test
were used to analyze the data. *P < 0.05; **p < 0.01; ***p < 0.001 vs. Sham + saline group; #p < 0.05; ##p < 0.01; ###p < 0.001 vs. SNL + saline group
(See figure on previous page.)
Fig. 6 Co-administration of DM (10 mg/kg, i.p.) and oxycodone (1 mg/kg, s.c.) enhanced the effect of oxycodone to suppress SNL-induced activation
of microglia in the L5 spinal cord dorsal horn. (a) Representative immunofluorescent images of microglia stained with iba1 (green; marker for activated
microglia) on day 14 is shown for the following groups: Sham (ipsilateral), SNL (contralateral), SNL (ipsilateral), SNL-DM10 (DM 10 mg/kg, i.p.; ipsilateral),
SNL-O1 (oxycodone 1 mg/kg, s.c.; ipsilateral), and SNL-O1 + DM10 (co-administration of oxycodone and DM; ipsilateral) (magnification: 20X). Scale bar,
50 μm. (b) Quantification of iba1-immunoreactivity after normalization for each group compared with control group (Sham+ saline) on day 14. Data
are presented as means ± S.E.M. (n≥ 5). One-way ANOVA and Newman-Keuls test were used to analyze the data. *P < 0.05, **p < 0.01, ***p < 0.001 vs.
Sham + saline group; #p < 0.05, ###p < 0.001 vs. SNL + saline group; &p < 0.05 vs. SNL + O1 group
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memory [38]. Albers et al. (1992) reported that adverse ef-
fects of DM seem to be dose related [39]. It is well known
that DM is metabolized by O-demethylation through cyto-
chrome P450 2D6 (CYP2D6) to form its active metabolite,
dextrophan, and by N-demethylation to form 3-methoxy-
morphinan, through CYP3A4 [40]. Dextrophan and 3-
methoxymorphinan is then further N-demethylation and
O-demethylation through CYP3A4 and CYP2D6 to form
3-hydroxymorphinan [41]. Therefore, use of high doses of
DM may produce phencyclidine (PCP)-like effects from
the metabolic conversion of DM to its metabolite, dextro-
phan. In the current study, we selected a low dose of DM
(10 mg/kg, i.p.; DM10), which did not produce a significant
anti-allodynic effect by itself, so that we could investigate
whether it would potentiate the acute and/or chronic ef-
fects of oxycodone on suppressing neuropathic pain with
minimal side effects.
The acute effects of drug(s) in this study were tested
30 min after drug(s) administration every other day.
DM10 could potentiate the acute anti-allodynic effects
of oxycodone (1 mg/kg) when tested 30 min after drug
administration as shown in Fig. 3b. Since the acute anti-
allodynic effects of oxycodone at higher dose (3 mg/kg)
was already very good, we could not see further potenti-
ated effect of DM10 (Fig. 3c) at this dose of oxycodone.
Although we did not carry out the pharmacokinetic
study in mice, we surmise that the acute effects would
not last long because the half-life (t1/2) for the elimin-
ation of oxydocone is only 0.52 ± 0.04 h in S.D. rats [42]
and 3.7 ± 2.3 h in humans [43]. Therefore, when we
tested for the oxycodone effect about 1 h before daily
drug(s) administration in the morning, this can serve as
a measure for the long-term effects of drug(s) on SNL-
induced neuropathic pain. In terms of treatment of
chronic neuropathic pain, this is a more important
measure than the acute effects of drug(s) and we found
that combined treatment of DM10 with 3 mg/kg of oxy-
codone significantly alleviate chronic allodynia, better
than oxycodone alone (3 mg/kg, s.c.) (Fig. 4c). We did
not see the potentiated anti-allodynia effect of DM on
1 mg/kg of oxycodone (Fig. 4b) when we tested 1 h be-
fore drug administration. It certainly needs further
investigation.
It has been reported that spinal damage and peripheral
nerve damage both lead to physiological and morpho-
logical activation of glial cells, particularly astrocytes and
microglia [44]. This activation could be initiated by the
release of proinflammatory cytokines (IL-1β, IL-6 and
TNFα), glutamate and nitric oxide (NO) from glial cells.
These mediators can initiate and maintain neuropathic
pain, inducing hyperexcitability of nociceptive neurons in
the spinal cord dorsal horn. Increased expression of astro-
cyte markers (i.e., GFAP) and microglia markers (iba1)
have been observed in many neuropathic pain models,
such as chronic constriction injury (CCI), partial sciatic
nerve ligation (PSNL) [45], and spared nerve injury (SNI)
[46]. Ma & Quirion also reported a slight increase in
GFAP immunoreactivity of astrocytes on the ipsilateral
L4-5 spinal cord dorsal horn one week after PSNL, but a
dramatic increase of GFAP immunoreactivity 3 weeks
after PSNL [47]. The activation of glial was shown to be
directly involved in neuropathic pain, since glial inhibitors
exhibited anti-allodynic properties [48]. In our current
study, both astrocytes and microglia activation induced by
SNL caused changes in morphology, and increased the
immunoreactivity of GFAP and iba1 at the ipsilateral spinal
cord dorsal horn on day 14 after spinal nerve ligation
(Figs. 5 and 6). We did not determine the activation of as-
trocytes or microglia during the early period after SNL, be-
cause the chronic effects of drug(s) could be seen only
after 3 days of SNL. Chronic oxycodone treatment (1 mg/
kg, s.c.) significantly decreased the activated astrocytes and
microglia as we observed on day 14. A recent study has
shown that oxycodone maintained a long-term and strong
analgesic effect whereas the analgesic effect of morphine
gradually decreased after chronic treatment. This long-
term analgesic effect of oxycodone was due to up-
regulation of GABAB receptor expression in DRG neuron
under vincristine-induced neuropathic pain in rats [11]. A
recent report has shown that spinal nerve ligation induced
significant decrease of spinal GABAB expression which
could be prevented by inhibition of microglia activation
[10]. In our current study, we found that chronic oxy-
codone treatment decreased the activation of glial cells and
it was consistent with this report. Co-administration of
DM with oxycodone (1 mg/kg, s.c.) reversed the morph-
ology of activated glial cells in SNL mice and further de-
creased the activated astrocytes and microglia to almost
the same level as in the control group (sham+ saline)
(Figs. 5 and 6). This effect of DM may account for its ef-
fect on enhancing the anti-allodynic effect of oxy-
codone acutely and chronically. Several studies have
reported that nerve injury increases expression and secre-
tion of proinflammatory cytokines, TNF-α [49], IL-1β
[50], and IL-6 [51], which are required for the develop-
ment of pain hypersensitivity. It has been also demon-
strated that accumulation of morphologically activated
glial cells (microglia and astrocytes) releases pro-
inflammatory cytokines (TNF-α and IL-1β) in the spinal
dorsal horn. TNF-α and IL-1β not only enhance excitatory
neurotransmitter (i.e., glutamate) but also suppress inhibi-
tory neurotransmitter release from synaptic terminals and
increase the activity of NMDA receptors and its currents
in lamina II neurons [52]. It has been reported that DM
(12.5 mg/kg, i.p.) inhibits inflammatory mediators, includ-
ing cytokines (TNF-α, IL-1β and IL-6) and chemokines in
sepsis mice model [53]. Furthermore, our recent clinical
study showed that DM (60–120 mg/day, oral) attenuated
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plasma cytokine TNF-α, which has been increased in
methadone-treated heroin addicts [54]. Our present study
demonstrates that SNL induced high plasma levels of IL-
6, IL-1β, and TNF-α, and chronic oxycodone (1 mg/kg,
s.c.) suppressed all of them significantly (Fig. 7). DM by it-
self significantly suppressed the plasma levels of TNF-α
and IL-1β but not of IL-6. We also found a trend in which
DM potentiated the effect of oxycodone (1 mg/kg, s.c.) on
suppressing the plasma levels of IL-6, IL-1β and TNF-α,
although this did not achieve statistical significance.
These results suggest that the mechanism of DM for po-
tentiating the chronic effects of oxycodone on suppressing
SNL-induced allodynia may be related to its effects on
glial and proinflammatory cytokines. On the other hand,
we know that the mechanisms for neuropathic pain may
involve many factors other than activation of glial cells
and inflammatory mediators, such as central sensitization
and long-term potentiation (LTP) of nociceptive C-fibers,
lamina I neurons and low threshold mechano-sensitive
afferents [55, 56], etc. Therefore it is reasonable to see
a difference between the degree of the reduction in
GFAP-ir or pro-inflammatory cytokines and allodynia
as shown in our results.
As we mentioned previously, DM binds to NMDA re-
ceptors as a low-affinity non-competitive antagonist and
binds to sigma-1 receptor as a high-affinity agonist. NMDA
receptors are expressed on both microglia and astrocytes
[57], whereas sigma receptors are expressed in microglia
[58]. It has been reported that the activation of sigma re-
ceptors reduced reactive gliosis following stroke injury in
rats [59] and that sigma-1 ligands can modulate several
neurotransmitter systems through NMDA receptors [60].
Thus the observed DM effects could be due to both its an-
tagonistic activity on NMDA receptors and agonistic activ-
ity on the sigma receptors present in the glial cells.
Conclusions
In conclusion, our study indicates that DM can potenti-
ate the effects of oxycodone in suppressing SNL-induced
allodynia acutely or chronically in mice. Suppression of
the overactivation of glial cells (astrocytes and microglia)
and the following releases of pro-inflammatory cytokines
(IL-6, IL-1β, and TNF-α) might play important roles on
this effect. The combination of DM with oxycodone may
lower the dose of oxycodone and decrease the side ef-
fects of oxycodone, therefore providing beneficial effects
in early treatment of neuropathic pain.
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